Endocare restates prior results after audit review
This article was originally published in Clinica
Endocare, the Irvine, California-based ablation device firm, has restated its results for 2000 and 2001, and belatedly filed its 2002 results. It says it will shortly file its figures for the first two quarters of 2003, bringing it back into compliance with US Securities and Exchange Commission rules.
You may also be interested in...
Siemens Healthineers' product mix of diagnostics and imaging products meant it was in the middle of a very dynamic situation when COVID-19 struck.
The WHO’s new "living guideline" against remdesivir’s use in hospitalized patients notwithstanding, some key opinion leaders in India see a role for the antiviral, but underscore that COVID-19 is still in its infancy and all repurposed therapies for the disease still have a long way to go. They also see the US remdesivir studies as more robust.
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.